ArticleScientific reports2025
LncRNA TERRA in hybrid with DNA is a relevant biomarker for monitoring patients with meningioma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Epigenetic Alterations in Meningiomas-A Review.Biomedicines · 2026Review
- Atypical R-loops in cancer: decoding molecular chaos for therapeutic gain.Journal of translational medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Telomeric repeat-containing RNAs (TERRAs) are expressed from subtelomeric regions, as long non-coding RNAs responsible for maintaining telomere length and stabilizing the genome. After TERRA is transcribed (f-TERRA) from subtelomere regions, it hybridizes (h-TERRA) into telomeres and intergenic regions to maintain genome and telomere stability. Here, we separately determine changes in two TERRA fractions, f-TERRA and h-TERRA levels in relation to telomere length (TL) in first time meningioma patients with preoperative and postoperative comparisons with the control group. Since there is a lack of established biomarkers for monitoring meningiomas despite their high prevalence among primary brain tumors, this study was designed. Fifty patients and 44 healthy controls were included in this study. Real-time quantitative PCR (q-PCR) reactions were performed to determine telomere length (TL), f-TERRA and h-TERRA levels. Statistically significant differences were observed between the levels of f-TERRA, h-TERRA, telomere length (TL), compared with the healthy control group and patients. When postoperative blood h-TERRA levels were compared between the patient group and the control group, no statistically significant differences were observed. However, in the correlation analysis between postoperative tumor volume and postoperative blood h-TERRA levels, a positive, moderate and statistically significant relationship was found. This study highlights the importance of presenting the results by means of preoperative and postoperative comparisons of meningiomas. Based on the available information, we suggest that the levels of f-TERRA and h-TERRA could also be potential biomarkers for diagnostic, therapeutic, and following of meningiomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.